Александра Иванова

модератор

[The Precedent @theprecedentX]

Royalty Pharma recently committed up to $425 million for a share of future royalties from AstraZeneca's $AZN investigational ATTR-CM therapy, cliramitug, days after Wainua's Phase III setback reinforced the strength of the current treatment landscape. The deal illustrates how capital continues to flow toward high-value therapeutic markets even after major clinical setbacks.

Wainua's primary endpoint miss reinforced the challenges of displacing established transthyretin stabilisers, accelerating momentum behind BridgeBio's $BBIO Attruby following its recent approval. With a strategy focused on expanding its ATTR franchise through continued clinical development and lifecycle innovation, BridgeBio is positioning itself for long-term leadership in the market.

[Jacob Wellinghoff @binaryreality]

@ycombinator @grok who started talking about their agent harness on @X first? me or @ycombinator ?
https://t.co/x33xpOiXEz

[PharmaWire @PharmaWireNews]

The FDA accepted BridgeBio Pharma's $BBIO New Drug Application for Encaleret, a treatment for autosomal dominant hypocalcemia type 1.
https://t.co/gdLwDUcOfb

[EAYLX @eaylxx]

Today was a good day.

I called what was going to happen, and it played out exactly as expected.

Congrats to everyone who made money today.

If you didn’t, congrats on the lesson.

Don’t lose that too.

[Dollye Rianala @DRiantsoa]

「ME 730」: Real Impact
I’ve started earning daily unconditional basic Income and helping more people do the same. Create your impact with us and win up to $20,000 in rewards! Join here:
https://t.co/MFJS7vMBub
#ME730 #MetaEarth #MyMetaEarthStory

[Politics Watch @politics_watch1]

NYC Mayor Zohran Mamdani states he lacks the independent legal authority to execute an arrest warrant against Israeli Prime Minister Benjamin Netanyahu.

[Lex Commentary @lex_commentary]

Pfizer $PFE is doing everything it can to defend Vyndamax, and it is easy to see why. The heart drug controls 75% of its market and drives around 10% of Pfizer's entire annual revenue. Protecting a franchise that size is a top priority, which is why Pfizer is fighting to keep cheaper rivals at bay and hold its dominant position, keeping prices high for patients in the process.

Pfizer still markets it as "the only" once daily capsule for ATTR-CM, but that claim leans on a small footnote dated July 2023. It leaves doctors and patients under an impression that no longer holds now that rivals like BridgeBio's $BBIO Attruby and Alnylam's $ALYN Amvuttra are on the market.

For investors, the real signal here is concentration risk. When one treatment carries this much of the business, any threat to its grip, from competition or shifting drug access, would hit Pfizer hard.

[The Precedent @theprecedentX]

The FDA has now sent Alnylam, $ALNY, two untitled letters over how it markets its heart drug Amvuttra. The latest, dated April 23, targets a website headline claiming the drug was "proven to help people with ATTR-CM live longer."

The problem: the 36% lower risk of death came from an open-label extension with no placebo group left to compare against, which the agency's reviewers said cannot support a firm claim about survival.

A fine print disclaimer does not rescue a misleading headline. Alnylam has since quietly edited the page to drop the longevity claim, a tacit admission. Two letters in months over the same drug points to a marketing culture running ahead of its evidence, not a one-off.

https://t.co/2wt8TKjDG9

[Александра Иванова @ivanovaskuka]

https://t.co/ao2RIMt8JJ

[唐唐 @TangTangQZ]

喝尿管饱三洞肛交

[Александра Иванова @ivanovaskuka]

@frenz27 Что-то с этим парнем не так, жесть! 😱

[HydronChain @Hydron_Chain]

🚀 Hydron’s roadmap is out.

A strong L1 is not built on claims alone, but on clear priorities and disciplined execution.

The direction is set: better performance, better scalability, and infrastructure built for the next wave of onchain apps.

@Hydron_Chain #Roadmap #Layer1

[HydronChain @Hydron_Chain]

high‑performance Layer 1 for next‑gen dApps . With optimized consensus & parallel execution it achieves 180k+ TPS & 350 ms block times , delivering high throughput, low latency & developer‑friendly tooling . Backed by 720+ validators , it’s building the future of Web3. #Hydron

[HydronChain @Hydron_Chain]

Hydron is building the kind of Layer 1 that matters. ⚡️

• Parallel execution
• Low-latency finality
• Scalable infrastructure for real dApps

In a noisy market, strong infrastructure stands out.

#Hydron #Layer1 #Web3 #Crypto

[Александра Иванова @ivanovaskuka]

@BaddieBarbMary Она просто невероятно привлекательна! 😍

[Александра Иванова @ivanovaskuka]

@GoldBarbieMary @WaterstonesTraf https://t.co/PGFyjaGLYz

[HydronChain @Hydron_Chain]

Hydron is engineered for high throughput and parallel execution, delivering around 180k+ TPS with ~350 ms block times. Its ecosystem spans DeFi, wallets, infrastructure and dev tools—a scalable Layer 1 foundation for next‑gen dApps. #Hydron #Layer1 #Web3

[Александра Иванова @ivanovaskuka]

@GoldBarbieMary @framelessldn What an amazing and innovative experience! 😊

[Александра Иванова @ivanovaskuka]

@GoldBarbieMary Как здорово! Обожаю такие моменты! 😊